Biologically based mental illness

OpenFold AI Research Consortium Welcomes Three New Members: UCB, NVIDIA and Valence Labs

Retrieved on: 
Tuesday, September 12, 2023
Software, Research, Pharmaceutical, Hardware, Oncology, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Health, Drug, CADD, Biologically based mental illness, Deep learning, CHARMM, Movement, UCB, Protein, Student, Patient, Machine learning, Dassault Systèmes, Drug discovery, Recursion, Physics, Artificial intelligence, Biology, Therapy, Neurology, Medical device, Pharmaceutical industry, Bayer, NVIDIA

UCB and Valence Labs expand OpenFold’s reach and support within the pharmaceutical and TechBio industries, while NVIDIA’s AI computing expertise will help accelerate the technical progress of the consortium.

Key Points: 
  • UCB and Valence Labs expand OpenFold’s reach and support within the pharmaceutical and TechBio industries, while NVIDIA’s AI computing expertise will help accelerate the technical progress of the consortium.
  • “AI as applied to proteins is one of the most promising areas for AI to have an impact on our day-to-day lives.
  • “Valence Labs is honored to join OpenFold and excited to contribute to the growing movement of democratizing machine learning research for the drug discovery community,” said Daniel Cohen, President of Valence Labs.
  • “Valence has a strong legacy of sharing our research and tools with the machine learning community, and we look forward to accelerating those efforts through the OpenFold consortium.”

Worldwide Market for Life Science Instrumentation to 2026: Market Opportunities, Expected Growth and Important Trends - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Health, Other Health, Comparative genomic hybridization, Analytic, Cell, Flow cytometry, HCS, Biologically based mental illness, Molecular biology, DNA, Peptide, Synthesizer, NGS, PCR, Biochemistry, SPR, Protein, RNA, Growth, Therapy, Oligonucleotide, Gene expression, Drug discovery, Animal, Laboratory, Global Assessment Report on Biodiversity and Ecosystem Services, Disease, Polymerase chain reaction, Electrophoresis, Global Assessment of Functioning, Electrophysiology, Metagenomics, CGH, Research, Medical device, Fine chemical, Vaccine, Microscope, Medical imaging

The "The Worldwide Market for Life Science Instrumentation, 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Worldwide Market for Life Science Instrumentation, 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The Worldwide Market for Life Science Instrumentation, 2021- 2026 is designed to provide total market knowledge for every significant life science instrumentation category.
  • This comprehensive report details the market opportunity expected growth and important trends in these essential instruments for manufacturing, control, research and development of biopharmaceutical therapies, as well as instruments used for basic life science research.
  • This section is directly extracted from the Global Assessment Report: The Analytical and Life Science Instrumentation Industry.

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Retrieved on: 
Monday, November 28, 2022
Marketing, COVID-19, Perforation, Biologically based mental illness, Incidence, Severe cognitive impairment, Mouth ulcer, Food, Hand, IND, Safety, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MSC, Disease, Neurotrophic keratitis, Protease, Security (finance), IgG4-related ophthalmic disease, Scar, Research, Coronavirus, Biologics license application, KALA, Eye, Infection, FDA, BLA, Pharmaceutical industry

ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for KPI-012 for the treatment of Persistent Corneal Epithelial Defect (PCED). Subject to acceptance of the IND by the FDA, Kala remains on-track to initiate a Phase 2b clinical trial of KPI-012 for PCED in the fourth quarter of 2022. Topline safety and efficacy data from the trial is expected in the first quarter of 2024. If positive, this trial could serve as the first of two pivotal trials needed to support the submission of a Biologics License Agreement (BLA) to the FDA. Following acceptance of the IND for KPI-012 by the FDA, Kala will receive the second tranche from the private placement of securities announced earlier today which, together with current cash on hand, Kala expects will extend its projected cash runway into the first quarter of 2025.

Key Points: 
  • Topline safety and efficacy data from the trial is expected in the first quarter of 2024.
  • If positive, this trial could serve as the first of two pivotal trials needed to support the submission of a Biologics License Agreement (BLA) to the FDA.
  • Persistent corneal epithelial defect, which is defined as a persistent non-healing corneal defect or wound that is refractory to conventional treatments, is a rare disease with an estimated incidence in the United States of 100,000 cases per year.
  • KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received orphan drug designation from the U.S. Food and Drug Administration.

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Retrieved on: 
Monday, November 28, 2022
Marketing, COVID-19, Perforation, United, Biologically based mental illness, Incidence, Severe cognitive impairment, Mouth ulcer, Food, IND, Safety, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Neurotrophic keratitis, Protease, Security (finance), Scar, Sale, Research, Biologics license application, Coronavirus, KALA, Eye, Infection, FDA, BLA, Pharmaceutical industry

Kala intends to use proceeds from the financing to advance the clinical development of KPI-012 for the treatment of PCED, as well as for general corporate purposes.

Key Points: 
  • Kala intends to use proceeds from the financing to advance the clinical development of KPI-012 for the treatment of PCED, as well as for general corporate purposes.
  • Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties.
  • Kala does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Retrieved on: 
Tuesday, November 1, 2022
Biologically based mental illness, Marketing, Security (finance), Severe cognitive impairment, Nasdaq, Board of directors, Textbook, U.S. Securities and Exchange Commission, Health, Ophthalmology, University of California, San Francisco Fetal Treatment Center, American Society of Cataract and Refractive Surgery, GLOBE, Research, Industry, Board, Society, COVID-19, Physician, Program, Stargardt disease, University of California, San Diego Performance-Based Skills Assessment, UCI, University of California, Irvine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Eye, Education, Pathology, Coronavirus, University, NASDAQ, Cataract surgery, Private Securities Litigation Reform Act, KALA, Cataract, Refraction, Patient, Food, Corneal transplantation, Retinitis pigmentosa, Pharmaceutical industry, Biology

ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (Kala or the Company), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the appointment of Marjan Farid, M.D., to its Board of Directors.

Key Points: 
  • ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (Kala or the Company), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the appointment of Marjan Farid, M.D., to its Board of Directors.
  • Marjan is an outstanding addition to our Board of Directors.
  • She performs limbal stem cell transplants as well as artificial corneal transplantation for the treatment of patients with severe ocular surface disease.
  • Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye.

Kala Pharmaceuticals Announces Reverse Stock Split

Retrieved on: 
Thursday, October 20, 2022
Transfer, Bangladesh Securities and Exchange Commission, CUSIP, Retinitis pigmentosa, LLC, Stargardt disease, NASDAQ, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Security (finance), KALA, Coronavirus, Eye, Biologically based mental illness, Private Securities Litigation Reform Act, Food, Company, Marketing, Exercise, Nasdaq, GLOBE, COVID-19, Pharmaceutical industry

ARLINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (Kala or the Company), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares.

Key Points: 
  • ARLINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (Kala or the Company), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares.
  • The new CUSIP number for the Companys common stock following the reverse stock split will be 483119202.
  • It is not necessary for stockholders holding shares of the Companys common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish.
  • The reverse stock split will affect all stockholders uniformly and will not alter any stockholders percentage interest in the Companys equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share.

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
Stargardt disease, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, KALA, Food, GLOBE, Conference, Biologically based mental illness, Webcast, Retinitis pigmentosa, Eye, Pharmaceutical industry

ARLINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held virtually and in New York, NY.

Key Points: 
  • ARLINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held virtually and in New York, NY.
  • A pre-recorded fireside chat will be made available beginning Monday, September 12, 2022 at 7:00 a.m.
  • To access the webcast and subsequent archived recording of the fireside chat, please visit the Presentations section of the Kala website at http://kalarx.com .
  • Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, August 19, 2022
Stargardt disease, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, KALA, Food, Financial compensation, GLOBE, Company, Biologically based mental illness, Retinitis pigmentosa, Eye, Employment, Professional Football Compensation Committee, Pharmaceutical industry

ARLINGTON, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as an inducement award outside the Companys 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

Key Points: 
  • ARLINGTON, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as an inducement award outside the Companys 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
  • The Company granted stock options to purchase up to an aggregate of 35,000 shares of Kala Pharmaceuticals common stock to two new employees.
  • The grant was approved by the Compensation Committee and made as an inducement material to such employee entering into employment with Kala Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4).
  • Vesting of the options is subject to the employees continued service with Kala Pharmaceuticals through the applicable vesting dates.

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Retrieved on: 
Thursday, August 18, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bangladesh Securities and Exchange Commission, KALA, Stargardt disease, GLOBE, Private Securities Litigation Reform Act, Board, Security (finance), Research, Retinitis pigmentosa, Marketing, Biologically based mental illness, COVID-19, Company, Proxy, Eye, Coronavirus, NASDAQ, Board of directors, Food, Delaware General Corporation Law, Pharmaceutical industry

The shares of SeriesD Preferred Stock will be distributed to such recipients at 5:00p.m.

Key Points: 
  • The shares of SeriesD Preferred Stock will be distributed to such recipients at 5:00p.m.
  • Subject to certain limitations, each outstanding share of SeriesD Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of SeriesD Preferred Stock).
  • The SeriesD Preferred Stock will be uncertificated, and no shares of SeriesD Preferred Stock will be transferable by any holder thereof except in connection with a transfer by such holder of any shares of the Companys common stock held by such holder.
  • Further details regarding the SeriesD Preferred Stock will be contained in a report on Form8-K to be filed by the Company with the Securities and Exchange Commission.

Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

Retrieved on: 
Monday, August 8, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, KALA, Stargardt disease, GLOBE, Research, Biologically based mental illness, Eye, NASDAQ, Food, Retinitis pigmentosa, Pharmaceutical industry

ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022.

Key Points: 
  • ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m.
  • The dial-in number to access the conference call is 800-715-9871 using the conference ID 9372651.
  • Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye.